Phase 1 study of MWTX-003 in healthy volunteers
Latest Information Update: 20 May 2023
At a glance
- Drugs 9MW 3011 (Primary)
- Indications Iron overload; Polycythaemia
- Focus Adverse reactions
Most Recent Events
- 15 May 2023 According to a Disc Medicine media release, company entered into an exclusive licensing agreement with Mabwell Therapeutics in January 2023.
- 23 Jan 2023 New trial record
- 20 Jan 2023 According to a Disc Medicine media release, the trial is expected to initiate during 2H 2023.